Wells Fargo raised the firm’s price target on HCA Healthcare (HCA) to $481 from $452 and keeps an Equal Weight rating on the shares. The firm cites in-line Q4 2025 results and better-than-expected 2026 guidance, with upside vs. its previous estimates driven by a stronger “core” growth assumption, modestly lower gross exchange headwind, and modestly larger offsets.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HCA:
- HCA Healthcare price target raised to $555 from $525 at RBC Capital
- HCA Healthcare price target raised to $529 from $490 at TD Cowen
- HCA Healthcare price target raised to $598 from $525 at UBS
- HCA Healthcare price target raised to $540 from $500 at Oppenheimer
- HCA Healthcare price target raised to $588 from $525 at Cantor Fitzgerald